PALO ALTO, Calif., Feb. 15 /PRNewswire/ -- Increasing adoption of biotherapeutics presents tremendous growth opportunities for companies offering cell culture products. Formulating serum-free media for specific cell lines used in the manufacture of biotherapeutics is a significant challenge for market participants.
New analysis from Frost & Sullivan (http://www.healthcare.frost.com ), reveals that the U.S. Select Cell Culture Market earned revenue of $714.5 million in 2005 and estimates to reach $1226.6 million in 2012.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the latest analysis of the U.S. Select Cell Culture Market then send an e-mail to Melina Trevino - Corporate Communications at melina.trevino@frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.
"Growth in the biopharmaceutical manufacturing business is the most significant driver for this market," notes Frost & Sullivan Research Analyst Martin Nejat. "The number of therapeutic recombinant proteins that are in late stage clinical trials is indicative of the predicted growth for the media market."
The widening indication range of therapeutic mAbs is adding new groups of patients. The high specificity and binding capacity of mAbs, particularly the human type, are useful in making them selective for binding to tumor cells, infectious agents, and infected cells and other human biomaterials related to the target diseases. In addition, mAbs offer improved safety and tolerance profiles. Furthermore, mAbs are being recommended in serious chronic disorders such as cancer, cardiovascular ailments, autoimmune and inflammatory diseases.
Understanding end-user needs with regard to serum and media is critical for future success in the market.
"End-users need custom media formulations, with specific packaging and batch volume requirements, that meet regulation," explains Nejat. "The competitive advantage lies with media companies that provide pharmaceutical manufacturers with customized solutions for their specific cell culture needs."
Formulating a dynamic partnership to provide custom solutions to meet the challenges of end-users is key to future market success.
U.S. Select Cell Culture Market, a part of the drug discovery technologies and clinical diagnostics subscription, provides analysis and outlook for the market. This study has been segmented into Fetal Bovine Serum, Media, Growth Factors and Media Supplements. This research includes detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews are available to the press.
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit http://www.frost.com .
U.S. Select Cell Culture Market F629-55 Contact: Melina Trevino Corporate Communications - North America P: 210.247.2440 F: 210.348.1003 E: melina.trevino@frost.com Radhika Menon Theodore Corporate Communications P: +91 (044) 52044668 E: rmtheodore@frost.com Donna Jeremiah Corporate Communications - Asia Pacific P: +603 6304 5832 F: +603 6201 7402 E: djeremiah@frost.com Surbhi Dedhia Corporate Communications - India P: +91 22 2832 4705 Ext: 131 E: sdedhia@frost.comhttp://www.frost.com
Frost & SullivanCONTACT: Melina Trevino, Corporate Communications - North America,+1-210-247-2440, or fax +1-210-348-1003, or melina.trevino@frost.com , orRadhika Menon Theodore, Corporate Communications, +91-044-52044668, orrmtheodore@frost.com , or Donna Jeremiah, Corporate Communications - AsiaPacific, +603-6304-5832, or fax +603-6201-7402, or djeremiah@frost.com , orSurbhi Dedhia, Corporate Communications - India, +91-22-2832-4705 Ext: 131,or sdedhia@frost.com , all of Frost & Sullivan
